Mirna Inks Deal to Use Marina's Smarticle Delivery Technology with miRNA Mimics | GenomeWeb

By Doug Macron

Mirna Therapeutics this week announced that it has acquired the rights to use Marina Biotech's Smarticle liposomal delivery technology with a number of its therapeutic microRNA mimics, including its lead liver cancer candidate.

Under the terms of the deal, Mirna will be fully responsible for the development and commercialization of oncology drugs incorporating the technology, although Marina will provide certain undisclosed preclinical and process-development assistance.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: SNP reference panel from the Haplotype Reference Consortium, and more.

Halloran Consulting's Laurie Halloran lists at Stat News the mistakes she sees startup companies make when pursuing a clinical trial.

MIT researchers are using bees to collect and visualize urban microbiome samples, Wired reports.

Reliance on Excel leads to errors in gene name lists, a new Genome Biology paper reports.